Guillermo Arreaza-Rubin, MD
Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

As director for clinical immunology of diabetes program and the technologies for the diagnosis and diabetes control program, Dr Arreaza oversees a variety of research projects designed to improve diagnosis, treatment, and monitoring of this disease. His portfolio includes the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) program—which supports innovative research by small businesses that have the potential for commercialization—in areas related to immunology, diabetes, and other endocrine and metabolic diseases. Relevant research topics are drug discovery for diabetes and other endocrine diseases; new technologies for islet isolation, stem cell/regeneration, and transplantation; immune modulatory agents for the primary and secondary prevention of diabetes; inflammatory aspects of type 2 diabetes, and glucose control technologies. Also, oversees academic research on closed-loop systems/artificial pancreas development including the testing of novel glucose sensors and integrated pancreatic hormone replacement delivery technologies and a portfolio on cell replacement therapies. He is the program director for a new consortium focused on strategies to restore awareness of hypoglycemia in people with type 1 diabetes (IAH-C) including interventions with new technologies. In addition, he has been the program director for the Clinical Islet Transplantation (CIT) Consortium and the Clinical Islet Transplant Registry (CITR) and participate in the coordination of the human islet research network (HIRN) program as a program director for the consortium for modeling autoimmunity (CMAI) and the consortium on human islet biomimetics (CHIB). Represents the NIDDK on several trans-NIH and interagency working groups on metabolic monitoring, inflammatory processes, autoimmunity and medical devices development and performance surveillance.